Intercalated chemotherapy and erlotinib: a viable first-line option for patients with advanced NSCLC?
Department of Medical Oncology, the First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, 79 Qingchun Road, Hangzhou, Zhejiang, 310003, China.
Yulong
Y
Zheng
Department of Medical Oncology, the First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, 79 Qingchun Road, Hangzhou, Zhejiang, 310003, China.
Nong
N
Xu
Department of Respiratory Diseases, the First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, 79 Qingchun Road, Hangzhou, Zhejiang, 310003, China. Electronic address: drzjy@163.com.
Jianying
J
Zhou
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy*; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy*; D008297:Male